Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Obg-like ATPase 1 (OLA1) is an evolutionarily conserved ATPase and GTPase belonging to the Obg family of P-loop NTPases, more specifically the translation factor-related class (TRAFAC)[1][2][3]. OLA1 performs essential roles in eukaryotic cells including suppression of protein synthesis by inhibiting ternary complex (TC) formation during translation initiation, regulation of the integrated stress response (ISR) via direct interaction with eIF2, modulation of cell cycle progression, and involvement in DNA damage responses and cytoskeleton organization[2][3]. OLA1 is implicated in cancer, both as a negative regulator (its depletion enhances tumor growth and metastasis) and as a prognostic biomarker in certain tumors, notably breast cancer[3]. The enzyme exhibits higher affinity for ATP than GTP and displays both ATPase and GTPase activities, making it an exceptional example of altered nucleotide specificity within a distinct protein family[1]. No direct therapeutic drugs are available or documented for this molecular target.
Inhibition of ATPase/GTPase activity; Modulation of integrated stress response via eIF2 interaction; Regulation of translation and cell survival pathways
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Obg-like ATPase 1 (OLA1).